From the Adult CF Unit (T.S.F., D.S.N., M.J.W.) and Department of Radiology (C.M.), Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK; Institute of Life Course and Medical Sciences (T.S.F., P.S.M.) and Institute of Infection and Global Health (D.S.N., M.J.W.), University of Liverpool, Liverpool, UK; and Institute in the Park (University of Liverpool), Alder Hey Children’s Hospital, Liverpool, UK (P.S.M.).
Auto-generated profile, based on publicly available information
Martin Walshaw
From the Adult CF Unit (T.S.F., D.S.N., M.J.W.) and Department of Radiology (C.M.), Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK; Institute of Life Course and Medical Sciences (T.S.F., P.S.M.) and Institute of Infection and Global Health (D.S.N., M.J.W.), University of Liverpool, Liverpool, UK; and Institute in the Park (University of Liverpool), Alder Hey Children’s Hospital, Liverpool, UK (P.S.M.).
Dynamic chest radiography shows potential as a rapid and useful imaging tool to assess the effect of pulmonary exacerbations in cystic fibrosis. Background Although spirometry is an important marker in the management of pulmonary exacerbations in cystic fibrosis (CF), it is a forced maneuver and can generate aerosol. Therefore, it may be di...
12 November 2013 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Background: Repeated courses of intravenous (IV) aminoglycosides in cystic fibrosis (CF) patients are associated with cumulative nephrotoxicity. Targeting their delivery through the inhaled route during acute pulmonary exacerbations may also be effective, but without systemic side effects. Methods: Using a randomized crossover trial design, in a pilot study we compared 14 days of IV tobramycin with nebulized tobramycin 300 mg twice a day (TNS) in acute respiratory exacerbations in 20 CF adults chronically infected with Pseudomonas aeruginosa (Psa) . Patients also received IV colistin in both arms. Results: Improvement in spirometry was similar between the two groups [mean change in FEV 1 % predicted: IV group 16.4 (standard deviation 8.5) versus TNS group 19.9 (11.3), p =0.26], but there was more suppression of sputum Psa in the TNS group [mean difference between treatments 0.85 log 10 colony-forming units/mL (CI 0.03 to 1.67), p =0.05]. IV tobramycin was associated with a greater urinary protein leak [mean difference between treatments 0.59 mg/24 hr (0.30 to 0.87), p =0.0005] and higher urinary levels of markers of acute renal tubular injury: N -acetylglucosaminidase [0.72 IU/mmol (0.37 to 1.07), p =0.0004], alanine aminopeptidase [1.19 IU/mmol (0.70 to 1.68), p =0.0001], and β 2 -microglobulin [0.44 μg/mmol (0.16 to 0.72), p =0.0046] than TNS. Compared with IV tobramycin, TNS treatment prolonged the time to next exacerbation requiring hospitalization ( p <0.001). Patient satisfaction was similar with both treatments, and no serious adverse effects were recorded. Conclusions: TNS is effective in treating acute exacerbations of Psa in CF patients, but with a renal sparing potential compared with the IV preparation.
Background Sleep apnoea can result in traffic accidents, and the British Lung Foundation's (BLF) “Snoring and Sleep Apnoea” and the Driver and Vehicle Licensing Agency's (DVLA) “Think! Tiredness can kill” leaflets are commonly used to inform patients about this. We wished to assess the impact of such knowledge on the general understanding and motivation of patients undergoing formal assessment for sleep apnoea in a sleep clinic. Methods In a prospective survey, patients were provided with the above leaflets when they underwent the sleep study, and completed a structured questionnaire when attending the results clinic several weeks later. Results 125 consecutive patients (92 male) with a mean (SD) age of 51 (14) years, BMI of 33.6 (6.9) and Epworth Sleepiness Scale of 10 (6) completed the questionnaire. 51 (41%) were eventually diagnosed with significant obstructive sleep apnoea/hypopnoea syndrome (OSAHS) requiring referral for continuous positive airway pressure therapy. 105 patients (84%) read the BLF leaflet and 91 (87%) assumed they understood about sleep apnoea from it. 28 (27%) believed they had sleep apnoea, 26 (25%) believed they did not, while the remainder (48%) were unsure. Although 28 (27%) became more worried about themselves, 56 (53%) were more keen to undertake the tests but 5 (5%) were not. 92 participants (74%) were current drivers and 84 (91%) read the DVLA leaflet. Only 10 of these (12%) thought they might have a disorder that could impact on their driving abilities although 38 (45%) were concerned they might not be allowed to drive in future. However, only 4 (5%) were discouraged to undertake the tests because of this. Overall, most patients (80%) found these leaflets informative and easy to understand. Conclusions These leaflets appear to improve patients' understanding of OSAHS and its implications, particularly regarding driving. Although they can engender concern and anxiety among some, the majority of patients felt motivated to undertake the tests. Improving the level of patient education and awareness through such leaflets may positively influence their involvement in overall management, potentially improving compliance and outcomes in the long term.
BACKGROUND: Although the evolution and adaptation of Pseudomonas aeruginosa (PA) populations during chronic lung infections of cystic fibrosis (CF) patients has been well studied, much less is known in non-CF bronchiectasis (BE). AIMS: Using isolates from 93 BE patients known to have chronic PA infection (enrolled in a trial of nebulised antibiotic therapy), we used whole genome sequencing to (i) assess the diversity of PA strains causing infections, (ii) assess the prevalence of multi-lineage (strain) infections, (iii) look for evidence for cross-infection or common source acquisition and (iv) characterise both adaptive mutations and within-population heterogeneity. METHODS: Using the Illumina platform, 189 isolates were genome sequenced, obtained from 93 patients attending 16 adult UK BE centres. Genomic data were used for typing by multilocus sequence type (MLST) and core genome SNP phylogeny, and to analyse genetic variations. RESULTS: The BE isolates were widely distributed within the global PA population structure. Of 23 patients from whose samples multiple isolates were examined, there were 6 examples of multi-lineage infections. SNP phylogeny revealed examples of more than one patient attending the same centre being infected with a common lineage. CONCLUSIONS: During infections of BE patients, PA populations adapt by accumulating loss of function mutations, leading to switches in phenotypes such as mode of iron acquisition and the production of biofilm-associated polysaccharides. As in CF, infecting PA populations exhibit considerable within-patient heterogeneity Supported by UK MRC as part of the BRONCH-UK network.
Cardiac sarcoidosis and cystic fibrosis (CF) are both rare conditions and their co-existence has not previously been noted in adults. For the first time we report a case of isolated cardiac sarcoidosis in a woman with CF, and discuss the possible combined aetiological factors. As the life expectancy of people with CF continues to increase, clinicians should be aware of the emergence of concomitant inflammatory conditions typically diagnosed in adulthood, and the diagnostic challenges this may present.